Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study

N/ANot Yet RecruitingNCT07033624

Harbin Medical University10,000 enrolled

Overview

The aim of this prospective cohort study is to collect the multi-omics profile of cardiovascular disease (CVD) high-risk individuals in Harbin, and to discover novel biomarker signatures of major adverse cardiovascular events (MACE) during a minimum 2-year follow-up period.

This is a single-center, observational, prospective cohort study. The primary endpoint is the incidence of MACE. Participants must meet at least two of the following criteria: hypertension, hyperglycemia, hyperlipidemia, or obesity. Baseline data and biological samples will be collected at enrollment, with clinical outcomes monitored for a minimum of two years. The study aims to enroll 10,000 participants aged 45 years and older from Harbin city, located in northeastern China.

Study Type

OBSERVATIONAL

Enrollment

10,000

Conditions

Cardiovascular Diseases

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1.Residents of Harbin city, regardless of gender. * 2.Meets at least two of the following conditions: diabetes, hypertension, hyperlipidemia, or obesity. * 3.No history of cardiovascular or cerebrovascular diseases. * 4.Willing to participate in the study and sign the informed consent form Exclusion Criteria: * 1.History of antibiotic or probiotic treatment within the past month. * 2\. Pregnant women. * 3\. History of autoimmune diseases or malignant tumors; severe heart, liver, or kidney dysfunction; or a history of severe cardiovascular or cerebrovascular diseases. * 4\. Any unstable condition or situation that may jeopardize patient safety or compliance. * 5\. Patients unable to provide informed consent due to physical reasons or unwilling to participate.

Locations (1)

The Second Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Outcomes

Primary Outcomes

Major adverse cardiovascular event (MACE)

A major adverse cardiovascular event (MACE) of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke

Time frame: 2 years

Secondary Outcomes

Cardiovascular death

Time frame: 2 years

All-cause death

Time frame: 2 years

Myocardial infarction

Time frame: 2 years

Stroke

Time frame: 2 years

Central Contacts

Haibo Jia, MD

CONTACT

15945685291_jhb101180@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.